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Abstract
This	receptor	family	comprises	a	group	of	receptors	for	the	calcitonin/CGRP	family	of	peptides.	The
calcitonin	(CT),	amylin	(AMY),	calcitonin	gene-related	peptide	(CGRP)	and	adrenomedullin	(AM)
receptors	(nomenclature	as	agreed	by	the	NC-IUPHAR	Subcommittee	on	CGRP,	AM,	AMY,
and	CT	receptors	[131,	74,	71])	are	generated	by	the	genes	CALCR	(which	codes	for	the	CT
receptor)	and	CALCRL	(which	codes	for	the	calcitonin	receptor-like	receptor,	CLR,	previously	known
as	CRLR).	Their	function	and	pharmacology	are	altered	in	the	presence	of	RAMPs	(receptor	activity-
modifying	proteins),	which	are	single	TM	domain	proteins	of	ca.	150	amino	acids,	identified	as	a
family	of	three	members;	RAMP1,	RAMP2	and	RAMP3.	There	are	splice	variants	of	the	CT	receptor;
these	in	turn	produce	variants	of	the	AMY	receptor	[131],	some	of	which	can	be	potently	activated	by
CGRP.	The	endogenous	agonists	are	the	peptides	calcitonin,	α-CGRP	(formerly	known	as	CGRP-I),	β-
CGRP	(formerly	known	as	CGRP-II),	amylin	(occasionally	called	islet-amyloid	polypeptide,	diabetes-
associated	polypeptide),	adrenomedullin	and	adrenomedullin	2/intermedin.	There	are	species
differences	in	peptide	sequences,	particularly	for	the	CTs.	CTR-stimulating	peptide	(CRSP)	is	another
member	of	the	family	with	selectivity	for	the	CT	receptor	but	it	is	not	expressed	in	humans	[94].	CLR
(calcitonin	receptor-like	receptor)	by	itself	binds	no	known	endogenous	ligand,	but	in	the	presence	of
RAMPs	it	gives	receptors	for	CGRP,	adrenomedullin	and	adrenomedullin	2/intermedin.	There	are
several	approved	drugs	that	target	this	receptor	family,	such	as	pramlintide,	erenumab,	and	the
"gepant"	class	of	CGRP	receptor	antagonists.
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